Craig Hofmeister C MD

Craig Hofmeister C MD
Asst Professor - ClinicalCollege of Medicinehofmeister.7@osu.edu
B321 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-7807Fax: (614) 293-7526
  • Leukemia Research

General Research Interest

I am a clinical investigator with interest in experimental therapeutics in Multiple Myeloma.

Research Description

Our research focuses primarily on phase I/II drug development in Multiple Myeloma with a focus on novel drugs.  Initial research into the immunodeficiencies of myeloma and its connection with quality of life are just beginning.

Transinstitutional Work

We are an active member of the Multiple Myeloma Research Consortium (MMRC), a group of 15 leading institutions focused on rapid drug development in Multiple Myeloma. 

Current Publications

  • Rocci A, Hofmeister CC, Pichiorri FThe potential of miRNAs as biomarkers for multiple myeloma.Expert Rev Mol Diagn in press 1-13 8/7/2014
  • Chu J, He S, Deng Y, Zhang J, Peng Y, Hughes T, Yi L, Kwon CH, Wang QE, Devine SM, He X, Bai XF, Hofmeister CC, Yu JGenetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells.Clin Cancer Res 20 3989-4000 8/1/2014
  • Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM Jr, Devine SM, Andritsos LAThe hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.Bone Marrow Transplant in press 7/28/2014
  • Patnaik A, Weiss GJ, Papadopoulos KP, Hofmeister CC, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo FC, Cotreau MM, Ramanathan RKPhase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.Br J Cancer 111 272-80 7/15/2014
  • Efebera YA, Sturm A, Baack EC, Hofmeister CC, Satoskar A, Nadasdy T, Nadasdy G, Benson DM, Gillmore JD, Hawkins PN, Rowczenio DNovel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred.Amyloid 21 110-2 6/1/2014
  • Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, Andritsos LA, Devine SMAprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study.Support Care Cancer in press 5/17/2014
  • Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, Isaia G, De Luca L, Rossi D, Gentili S, Uccello G, Consiglio J, Ria R, Benevolo G, Bringhen S, Callea V, Weiss B, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A, Pichiorri FCirculating miRNA markers show promise as new prognosticators for multiple myeloma.Leukemia in press 5/12/2014
  • He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu J, Chu J, Deng Y, Benson DMCS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.Leukemia 28 917-27 4/1/2014
  • Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KCPomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.Blood 123 1826-32 3/20/2014
  • Vasu S, Deng Y, Yuan S, Zhang J, Fan Z, Hofmeister CC, He X, Marsh HC, Devine SM, Yu J, He S, Chu JFLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome.Biol Blood Marrow Transplant 20 309-13 3/1/2014
  • Grever M, Byrd JC, Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TSA phase I trial of flavopiridol in relapsed multiple myeloma.Cancer Chemother Pharmacol 73 249-57 2/1/2014
  • Eicher DM, Lonial S, Cavallo F, Palumbo A, Nair B, Waheed S, Hofmeister C, Rogers HJHigh-risk myeloma: when to transplant-or not.Semin Oncol 41 e1-9 2/1/2014
  • Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ, Phelps MASensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.J Pharm Biomed Anal 88 262-8 1/1/2014
  • Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, Benson DM JrElotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.Cancer Immunol Immunother 62 1841-9 12/1/2013
  • Harshman SW, Canella A, Ciarlariello PD, Rocci A, Agarwal K, Smith EM, Talabere T, Efebera YA, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri FCharacterization of multiple myeloma vesicles by label-free relative quantitation.Proteomics 13 3013-29 10/1/2013
  • Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MAStandard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.Clin Pharmacokinet 52 705-12 8/1/2013
  • Heerema N, Byrd JC, Devine SM, Efebera YA, Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham JEarly versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.Leuk Lymphoma 54 1658-64 8/1/2013
  • He S, Chu J, Wu LC, Mao H, Peng Y, Alvarez-Breckenridge CA, Hughes T, Wei M, Zhang J, Yuan S, Sandhu S, Vasu S, Benson DM Jr, Hofmeister CC, He X, Ghoshal K, Devine SM, Caligiuri MA, Yu JMicroRNAs activate natural killer cells through Toll-like receptor signaling.Blood 121 4663-71 6/6/2013
  • Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce CM, Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci AIn vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.J Exp Med 210 951-68 5/6/2013
  • Clark JI, Greene JB, Lau Clark A, Dalal JS, Hofmeister CCPhase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.Med Oncol 30 358 3/1/2013
  • Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SSA phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.Blood 120 4324-33 11/22/2012
  • Phillips G, Elder P, Mastronarde JG, Devine SM, Hofmeister CC, Wood KL, Bruce JT, Tran JMChemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.Clin Lymphoma Myeloma Leuk 12 325-9 10/1/2012
  • Mori S, Crawford BS, Roddy JV, Phillips G, Elder P, Hofmeister CC, Efebera Y, Benson DM JrSerum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.Hematol Oncol 30 156-62 9/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu